Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C32H63NO3
Numéro CAS:
Poids moléculaire :
509.85
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
C14 Ceramide (d18:1/14:0), Avanti Research™ - A Croda Brand 860514P, powder
assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 25 mg (860514P-25mg), pkg of 1 × 5 mg (860514P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand 860514P
lipid type
sphingolipids
shipped in
dry ice
storage temp.
−20°C
SMILES string
OC[C@]([H])(NC(CCCCCCCCCCCCC)=O)[C@]([H])(O)/C=C/CCCCCCCCCCCCC
InChI
1S/C32H63NO3/c1-3-5-7-9-11-13-15-16-18-19-21-23-25-27-31(35)30(29-34)33-32(36)28-26-24-22-20-17-14-12-10-8-6-4-2/h25,27,30-31,34-35H,3-24,26,28-29H2,1-2H3,(H,33,36)/b27-25+/t30-,31+/m0/s1
InChI key
ZKRPGPZHULJLKJ-JHRQRACZSA-N
General description
Ceramide synthesis is majorly driven by de novo pathway involving the palmitoyl-CoA and L-serine, and also by salvage pathway via recycling of complex sphingolipids. The ceramide transporter, Cert mediates the transfer of C14 from smooth endoplasmic reticulum to Golgi. Ceramide synthase CerS6 enzyme is involved in the synthesis of C14 ceramide.
Application
C14 Ceramide (d18:1/14:0) is suitable for use
- as a standard in high-performance liquid chromatography/tandem mass spectrometry (LC/MS2) for ceramide quantification from muscel biopsies
- in lipid monolayer preparation for biophysical studies
- in the morphological and dimensional evaluation studies
Biochem/physiol Actions
Ceramides regulate biological processes including proliferation, differentiation and apoptosis. In the cystic fibrosis patients, elevated levels of C14 ceramide is observed. It is also a potential biomarker for hepatic steatosis (HS) and C14 ceramide levels correlate with the aspartate aminotransferase (AST) / alanine transaminase (ALT) ratio. Tumor necrosis factor α (TNFα) mediates increase in the C14 levels. Fumonisin B1 prevents the C14 accumulation.
Packaging
5 mL Amber Glass Screw Cap Vial (860514P-25mg)
5 mL Amber Glass Screw Cap Vial (860514P-5mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
Classe de stockage
11 - Combustible Solids
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Ceramide effects in the bicelle structure
Barbosa-Barros L, et al.
Colloids and Surfaces. A, Physicochemical and Engineering Aspects, 317(1-3), 576-584 (2008)
Tumor necrosis factor-alpha(TNFalpha)-induced ceramide generation via ceramide synthases regulates loss of focal adhesion kinase (FAK) and programmed cell death
Hernandez-Corbacho M, et al.
The Journal of Biological Chemistry, 290(42), 25356-25373 (2015)
Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain
Garic D, et al.
Progress in Lipid Research (2019)
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 860514P-5MG | 04061835317547 |